Your browser is no longer supported. Please, upgrade your browser.
MTEM Molecular Templates, Inc. daily Stock Chart
Molecular Templates, Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own7.72% Shs Outstand27.29M Perf Week-2.54%
Market Cap251.61M Forward P/E- EPS next Y-0.91 Insider Trans0.00% Shs Float24.82M Perf Month4.06%
Income-20.90M PEG- EPS next Q-0.20 Inst Own21.30% Short Float0.50% Perf Quarter30.97%
Sales2.60M P/S96.77 EPS this Y-156.50% Inst Trans4.03% Short Ratio1.25 Perf Half Y42.95%
Book/sh4.90 P/B1.88 EPS next Y31.10% ROA-60.80% Target Price17.50 Perf Year32.75%
Cash/sh- P/C- EPS next 5Y- ROE-110.90% 52W Range3.85 - 13.25 Perf YTD-7.98%
Dividend- P/FCF- EPS past 5Y9.60% ROI- 52W High-30.42% Beta3.11
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low139.48% ATR0.55
Employees24 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)46.34 Volatility5.71% 5.58%
OptionableNo Debt/Eq0.05 EPS Q/Q-12.40% Profit Margin- Rel Volume0.45 Prev Close8.65
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume98.57K Price9.22
Recom1.00 SMA200.64% SMA50-9.40% SMA20020.59% Volume44,196 Change6.59%
Mar-19-18 04:01PM  Molecular Templates to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-15-18 08:00AM  New Data on Molecular Templates Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018 GlobeNewswire
Mar-08-18 08:00AM  Molecular Templates to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-02-18 04:30PM  Molecular Templates Closes $10 Million Debt Facility with Perceptive Advisors GlobeNewswire
Jan-30-18 07:45AM  New Research: Key Drivers of Growth for Fidus Investment, Athenex, Threshold Pharmaceuticals, Cintas, GNC, and Hillenbrand Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-05-18 08:00AM  Molecular Templates Provides Corporate Update and Outlines 2018 Milestones GlobeNewswire +10.86%
Dec-19-17 01:55PM  Did Molecular Templates Inc (NASDAQ:MTEM) Create Value For Shareholders? Simply Wall St. +9.10%
Nov-21-17 04:01PM  Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-17 04:15PM  Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer GlobeNewswire
04:01PM  Molecular Templates, Inc. Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-24-17 08:52AM  Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL) GlobeNewswire
Oct-06-17 08:00AM  Molecular Templates to Present at the 2017 BIO Investor Forum GlobeNewswire +16.26%
Sep-22-17 01:54PM  Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences GlobeNewswire
Sep-06-17 02:17PM  Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference GlobeNewswire
Sep-05-17 12:41PM  5 of the Best Stocks Under $10 for 2017 Zacks +5.13%
Aug-31-17 10:10AM  Molecular Templates, Inc. (Nasdaq: MTEM) to Ring the Nasdaq Stock Market Closing Bell GlobeNewswire +6.86%
Aug-30-17 08:30AM  Molecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017 GlobeNewswire
Aug-14-17 08:00AM  Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire -9.86%
Aug-10-17 08:00AM  Molecular Templates Potential Catalysts, Merger Synergies and Pipeline Review ACCESSWIRE
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.